Apel­lis joins the grow­ing num­ber of bio­phar­mas scrap­ping a failed Covid-19 pro­gram af­ter an ear­ly flop

The glob­al pan­dem­ic set off a fren­zy of R&D ac­tiv­i­ty as biotechs around the world scram­bled to see if they could come up with a new med­ica­tion or vac­cine to help fight back. But even as the mR­NA stand­outs are high­light­ing the mar­ket El Do­ra­do open to suc­cess­ful teams, the fail­ures are start­ing to pile up.

Thurs­day af­ter­noon it was Apel­lis’ $APLS turn to deep-six a new drug.

The biotech re­ports that their C3 ther­a­py APL-9 had failed to move the nee­dle on mor­tal­i­ty when com­bined with stan­dard of care, as com­pared to SOC alone.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER